Bionure
Bionure is a biotechnology company founded in 2009 with the mission to develop new treatments to prevent brain damage and slow the progression of neurological diseases such as Multiple Sclerosis, Parkinson's, Epilepsy, and Alzheimer's. The company focuses on accelerating new therapies for the nervous system, utilizing technologies like chemical compounds, monoclonal antibodies, recombinant proteins, peptides, and oligonucleotides. Bionure's strategy involves investing in biotech companies, managing risks through diversification, and aiming for exit strategies within 2 to 5 years. Their research spans from pre-clinical to Phase II clinical trials, with a current market size of $80 billion in the nervous system sector.
Industries
Nr. of Employees
small (1-50)
Bionure
Carrer Sant Joan de Malta, 145, 08018 Barcelona, Spain
Products
ACT01 (BN201)
A peptidomimetic small-molecule candidate with reported neuroprotective activity and efficacy in animal models (developed for indications including multiple sclerosis and glaucoma).
ACT02
A peptidomimetic compound reported to have neuroprotective activity with efficacy in animal models relevant to Parkinson's disease and cognitive impairment.
ACT03
A gelatinase inhibitor peptidomimetic candidate with reported neuroprotective effects; shown to reduce gliosis in a rat model of epilepsy and to attenuate inflammation and loss of barrier integrity in vitro.
ACT01 (BN201)
A peptidomimetic small-molecule candidate with reported neuroprotective activity and efficacy in animal models (developed for indications including multiple sclerosis and glaucoma).
ACT02
A peptidomimetic compound reported to have neuroprotective activity with efficacy in animal models relevant to Parkinson's disease and cognitive impairment.
ACT03
A gelatinase inhibitor peptidomimetic candidate with reported neuroprotective effects; shown to reduce gliosis in a rat model of epilepsy and to attenuate inflammation and loss of barrier integrity in vitro.
Services
Investment and funding of biotech companies and programs to advance preclinical assets into clinical development and proof-of-concept.
Out-licensing of drug candidates to third parties to complete later-stage clinical trials and commercialization.
Preclinical efficacy testing, in vitro BBB and inflammation assays, and biomarker development to support dose and patient selection strategies.
Investment and funding of biotech companies and programs to advance preclinical assets into clinical development and proof-of-concept.
Out-licensing of drug candidates to third parties to complete later-stage clinical trials and commercialization.
Preclinical efficacy testing, in vitro BBB and inflammation assays, and biomarker development to support dose and patient selection strategies.
Expertise Areas
- Neurotherapeutics development
- Preclinical translational pharmacology
- Biomarker development and patient stratification
- RNA-based therapeutics
Key Technologies
- Peptidomimetics
- Small-molecule CNS drug discovery
- Monoclonal antibody development
- Recombinant protein engineering
News & Updates
Announcement of Dr. Ricard Mis joining as Scientific Director, bringing over 25 years of experience in biotech research and development.
The gelatinase inhibitor ACT-03 reduces gliosis in a rat epilepsy model and attenuates inflammation and barrier loss in vitro.
Carmen Sanfrancisco appointed as CEO after Salut Monràs, with a focus on neurodegenerative pathologies.
Pere Monràs takes over as President, leading the company in new strategic directions.
Announcement of Dr. Ricard Mis joining as Scientific Director, bringing over 25 years of experience in biotech research and development.
The gelatinase inhibitor ACT-03 reduces gliosis in a rat epilepsy model and attenuates inflammation and barrier loss in vitro.
Carmen Sanfrancisco appointed as CEO after Salut Monràs, with a focus on neurodegenerative pathologies.
Pere Monràs takes over as President, leading the company in new strategic directions.